|
VOTED AS AMERICA'S TOP UROLOGISTS A Division of Westchester Medical Group Pharmacology for renal calculi Blair B and Fabrizio M. Portsmouth Naval Hospital, Portsmouth, Virginia, USA. Expert Opin Pharmacother. 2000 Mar;1(3):435-41. Stone disease is as old as recorded history but despite advances in diagnosis and treatment, it continues to cause significant morbidity. This review summarizes the current pharmacologic management of urinary calculi based upon the stone type. All patients with stone disease are advised to increase fluid intake, limit dietary protein and limit sodium. Calcium oxalate stones can be managed on a selective or non-selective basis depending on the cause of the hypercalciuria or hyperoxaluria. Agents currently in use include sodium cellulose phosphate, thiazides, orthophosphates, oral calcium supplements, pyridoxine, cholestyramine, citrate, magnesium and allopurinol. Classically, struvite stones occur in the presence of urea splitting organisms and are composed of magnesium, ammonium phosphate and carbonate apatite. The goal of treatment is to make patients stone free as bacteria retained in stone fragments lead to stone growth. Urease inhibitors, aluminium hydroxide gel, hemiacidrin, and Suby G and M solutions are infrequently used in treatment. Cystine stones are the result of an autosomal recessive disorder. D-Penicillamine, captopril and alpha-mercaptopropionylglycine (MPG) are all oral agents that have proven to be efficacious. As more randomised trials are conducted and the understanding of endogenous stone inhibitors progresses, the medical management of stone disease will continue to improve.
Center for Robotics, Laparoscopy, and Advanced Urology Westchester Medical Group 210 Westchester Avenue Department of Urology White Plains, NY 10604 Tel: 914.682.6470 Fax: 914.681.5264 VIEW MAP >>
1 Theall Road Visit Westchester Medical Group's website at www.westchestermed.com 
|